CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer

BMC Cancer

Table 2 Survival by category of CA19–9 and platelet level in advanced pancreatic cancer patients

	No. of cases	No. of events	PFS			OS
	No. of cases	No. of events	Univariate HR (95% CI)	Multivariate HR^* (95% CI)	No. of events	Univariate HR (95% CI)	Multivariate HR^* (95% CI)
Baseline CA19–9 level
< 1365 U/ml (median)	100	90	1 (reference)	1 (reference)	74	1 (reference)	1 (reference)
≥ 1365 U/ml	100	93	1.53 (1.14–2.06)	1.76 (1.27–2.43)	81	1.61 (1.17–2.21)	1.93 (1.34–2.77)
Change in CA19–9 level at week-6†
Per unit decreases of CA19–9	200	183	0.86 (0.78–0.95)	0.86 (0.78–0.95)	155	0.87 (0.79–0.96)	0.84 (0.75–0.94)
Baseline Platelet level
Tertile 1 (lowest)	66	59	1 (reference)	1 (reference)	50	1 (reference)	1 (reference)
Tertile 2	67	64	1.28 (0.90–1.83)	1.21 (0.83–1.77)	52	1.15 (0.78–1.70)	1.02 (0.67–1.54)
Tertile 3 (highest)	67	60	0.93 (0.65–1.34)	0.95 (0.64–1.41)	53	0.88 (0.60–1.31)	0.86 (0.56–1.31)

* The multivariable, stage (stage III vs. stage IV)-stratified Cox regression model initially included age (continuous), sex (female vs. male), KPS (70–80 vs. 90–100), prediagnosis body mass index (continuous), tumor location (head/uncinate vs. body/tail vs. overlapping sites), diabetes mellitus (absent vs. present), chemotherapy regimen (Gemcitabine monotherapy vs. Gemcitabine plus 5-Fu vs. Gemcitabine plus nab-PTX vs. Gemcitabine plus DDP vs. Nab-PTX plus S-1), and radiotherapy (yes vs. no). A backward elimination with a threshold of P = 0.05 was used to select variables in the final models
† CA19–9 change = ([CA19–9 at week-6]-[CA19–9 at baseline]) / (CA19–9 at baseline); per unit equals a 100% decrease
Abbreviations: CI, confidence interval; HR, hazard ratio; KPS, Karnofsky Performance Status; PFS, progression-free survival; OS, overall survival

ISSN: 1471-2407